Reviva Pharmaceuticals Holdings (RVPH) risk factors

72 risks, 2 dropped, 11 reworded since the prior year. The company faces a Nasdaq minimum bid price deficiency notice, threatening delisting of its common stock. Insider ownership concentration decreased significantly from 34.16% to 12.7%.

74 risks. Reviva Pharmaceuticals faces substantial going concern doubt with an accumulated deficit of $164.3 million and zero product revenues. The business is heavily dependent on the clinical success and regulatory approval of its lead drug candidate, brilaroxazine. Operations are constrained by a tiny headcount of fourteen employees and a heavy reliance on future external financing.